Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

28.70USD
17 Nov 2017
Change (% chg)

$-0.34 (-1.17%)
Prev Close
$29.04
Open
$28.88
Day's High
$28.97
Day's Low
$28.52
Volume
30,713
Avg. Vol
47,924
52-wk High
$34.02
52-wk Low
$26.43

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $998.34
Shares Outstanding(Mil.): 34.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

Nov 08 2017

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

Sep 13 2017

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Genomic Health Q2 loss per share $0.08

* Genomic Health announces second quarter 2017 financial results and reports recent business progress

Aug 01 2017

Earnings vs. Estimates